Modjtahedi BS, et al. - Researchers conducted a matched retrospective cohort study to describe the visual outcomes and the treatment course of patients with exudative age-related macular degeneration (AMD) based on ocular hypotensive use. The sample consisted of patients (n = 234) enrolled in the Kaiser Permanente Southern California health plan. Using pharmacy dispensing data, patients taking ocular hypotensives were identified and were matched to controls to compare visual acuity, number of anti-VEGF injections, and conversation to secondary anti-VEGF agents in the first year of treatment. Compared with those not taking ocular hypotensives, individuals with concurrent glaucoma and exudative AMD have comparable visual results and treatment courses. Although it was proposed that aqueous suppressants prolong anti-VEGF residence time, in this series, patients using these agents did not show visual benefit or a decreased injection burden.